Skip to content

A prospective, open label, single arm post-market study to assess effectiveness and safety of the base composition bath salt („Basis-Zusammensetzung Badesalz“) in healthy subjects

A prospective, open label, single arm post-market study to assess effectiveness and safety of the base composition bath salt („Basis-Zusammensetzung Badesalz“) in healthy subjects - BEST

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
DRKS
Registry ID
DRKS00017458
Enrollment
49
Registered
2019-07-08
Start date
2019-07-26
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Interventions

Group 1: Subjects will place one arm in a hand bath with warm water containing the base composition bath salt for 30 min on 2 consecutive days. Demographics and Medical History will be assessed at bas

Sponsors

Alexander Weltecke GmbH & Co. KG
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Male or female aged = 18 years on the day of screening 2) Subjects able to understand the informed consent and willing to participate as evidenced by providing informed consent. 3) Signed Informed Consent 4) Subjects able and willing to attend all scheduled visits and comply with all study procedures

Exclusion criteria

Exclusion criteria: 1) Known hypersensitivity to a component of the base composition bath salt 2) Open wounds 3) Active infections 4) Severe generalized disease resulting in a life expectancy shorter than 3 months 5) Pregnant or breast-feeding women 6) Women of childbearing potential without effective contraception 7) Alcohol- or drug abuse 8) Subjects with psychiatric disorders influencing their judgement or autonomy 9) Inability or unwillingness to understand or comply with required study procedures 10) Subjects who are not suitable for the study based on the principal investigator’s evaluation 11) Subjects who are financially or otherwise dependent on the principal investigator or sponsor. 12) Subjects who are imprisoned or have been institutionalized for medical reasons

Design outcomes

Primary

MeasureTime frame
Effectiveness - Increase in wellbeing will be assessed with a questionnaire before and after treatment

Secondary

MeasureTime frame
Safety- Safety will be assessed by measuring the incidence and prevalence of adverse events throughout the study. Effectiveness- Skin smoothness will be assessed before and after treatment by visual assessment and measured using a Sebumeter® Transepidermal water loss (TEWL) will be measured before and after treatment using a Tewameter® Skin pH will be measured before and after treatment using a skin pH meter

Countries

Germany

Contacts

Public ContactEva Kristina Bee

Praxis für Hautkrankheiten Dr. med. Eva Kristina Bee

info@hautarzt-drensteinfurt.de+49 (0) 2508 9999488

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026